Provided by Tiger Trade Technology Pte. Ltd.

Inhibrx Biosciences

96.99
-0.9400-0.96%
Post-market: 96.990.00000.00%19:30 EDT
Volume:201.45K
Turnover:19.64M
Market Cap:1.42B
PE:-10.93
High:100.13
Open:99.30
Low:96.07
Close:97.93
52wk High:155.29
52wk Low:28.16
Shares:14.67M
Float Shares:8.64M
Volume Ratio:0.84
T/O Rate:2.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.8768
EPS(LYR):-9.0434
ROE:-1773.60%
ROA:-43.61%
PB:-26.86
PE(LYR):-10.72

Loading ...

CEO’s Bold Move Signals Growing Confidence in Biotech Challenger

TIPRANKS
·
Sep 29

Inhibrx CEO buys $998.8K in common stock as part of option exercise

TIPRANKS
·
Sep 29

Inhibrx Biosciences CEO Mark Lappe Acquires $984,588 of Common Shares

Reuters
·
Sep 29

Inhibrx Biosciences Updates Investor Presentation and Pipeline Outlook

TIPRANKS
·
Sep 29

Top Insider Makes Bold Move on Biotech Stock

TIPRANKS
·
Sep 24

Inhibrx Biosciences Director Jon Faiz Kayyem Acquires $500,000 of Common Shares

Reuters
·
Sep 24

Top Insider Makes Bold Move at Inhibrx Biosciences

TIPRANKS
·
Sep 18

Inhibrx Biosciences Director Jon Faiz Kayyem Acquires $500,000 in Common Shares

Reuters
·
Sep 18

Inhibrx Biosciences Director Kimberly Manhard Sells Common Shares Worth $115,467.50

Reuters
·
Sep 11

Inhibrx Biosciences reports strong Phase 2 INBRX-106 data

TIPRANKS
·
Sep 09

Inhibrx CEO Mark Lappe Reports Acquisition of 25,000 Common Shares Worth $2.59 Million

Reuters
·
Sep 09

Inhibrx Biosciences Shares Fall 22% After Co Releases Data from Mid-Stage Study of Its Experimental Combination Cancer Drug

THOMSON REUTERS
·
Sep 08

Analysts Offer Insights on NA Companies: First Horizon (FHN) and Inhibrx Biosciences Inc (INBX)

TIPRANKS
·
Sep 08

Inhibrx Biosciences Says Cancer Combination Therapy Shows Improved Response in Phase 2 Study

MT Newswires Live
·
Sep 08

Inhibrx Biosciences Reports Positive Study Results for Squamous Cell Carcinoma Treatment

Dow Jones
·
Sep 08

Inhibrx Says Phase 2 Trial Shows INBRX-106 Plus Pembrolizumab Lifts Response Rate to 48.3% in HNSCC

Reuters
·
Sep 08

Inhibrx Biosciences: Currently Conducting Phase 1/2 Study of Inbrx-106 in Perioperative Setting of Nsclc, with Initial Results Targeted by Mid-2027

THOMSON REUTERS
·
Sep 08

Inhibrx Biosciences Inc: Evaluating Potential of Inbrx-106 in Other Highly Immunogenic Tumor Types

THOMSON REUTERS
·
Sep 08

Inhibrx Biosciences - to Expand Phase 2 Study by 50 Hpv+ Patients

THOMSON REUTERS
·
Sep 08

Inhibrx Biosciences - Inbrx-106 Plus Pembrolizumab Achieves 48.3% Corr and 72.4% Six-Month Pfs Rate

THOMSON REUTERS
·
Sep 08